A Connected CD4-targeted Portfolio


TaiMed's portfolio spans an FDA-approved HIV therapy, clinical-stage long-acting antibody programs, and preclinical CD4-targeted research. Each program builds on a common foundation in CD4 biology while addressing a different stage of therapeutic innovation.

Trogarzo® | Multidrug-resistant HIV-1 | Commercial

Role: Clinical and commercial foundation for TaiMed's CD4-targeted approach.
  Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 

TMB-365/380 | HIV maintenance therapy | Phase 2b

Role: Lead clinical program; complete investigational long-acting dual-antibody regimen.
  Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 

TMB-365 | Long-acting HIV combination component | Phase 1 completed / combination development

Role: Next-generation CD4-targeted antibody used in TMB-365/380 and being considered for additional future combinations.
  Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 

CD4-ADC | HIV cure research | Preclinical

Role: Targeted delivery research directed at the latent HIV reservoir.
  Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market